Biotech Values

[DewDiligence]

QGEN/PFE collaborate on KRAS companion diagnostic for dacomitinib:

http://finance.yahoo.com/news/QIAGEN-and-Pfizer-Partner-to-prnews-2730719686.html?x=0&.v=1

Dacomitinib (a/k/a PF-00299804) is PFE’s HER-1/2/4 inhibitor for NSCLC. It is in phase-3 trials in the first-line metastatic setting (for patients who received Tarceva in the adjuvant setting) and the second-line metastatic setting (for patients who received chemo in the first line); results are expected in 2012 and 2013, respectively:

http://www.clinicaltrials.gov/ct2/show/NCT01000025
http://www.clinicaltrials.gov/ct2/show/NCT01360554

Financial terms for the QGEN-PFE collaboration have not been disclosed.